French allergy company DBV takes first step towards 2012 IPO
This article was originally published in Scrip
Allergy treatment specialist DBV Technologies has shown its first official sign of intent to make an initial public offering on the NYSE Euronext exchange this year with the filing of its "Document de Base" with the French financial regulator, the Autorité des marchés financiers (AMF). The precise timing of the IPO will depend on market conditions and is subject to the approval of the AMF.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.